Nuvalent shares surge 39% to record high as GSK agrees to $10.6 billion acquisition deal

As reported by mint - markets

Nuvalent's shares surged 39% to $123 after GlaxoSmithKline agreed to acquire the cancer drug developer for $10.6 billion, enhancing its oncology portfolio.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on mint - markets ↗

Market Samachar is a news aggregator. This article was originally published by mint - markets. Tap the button above to read the full story on their site.

INDIAN US stocks: SpaceX IPO demand is approaching four times oversubscribed, source says Markets-Economic Times
INDIAN Brent crude oil price falls below $90 a barrel on hopes of Iran deal Markets-Economic Times
COMPANIES PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake Stocks-Markets-Economic Times
COMPANIES Market Trading Guide: CCL Products among 2 stock recommendations for Wednesday Stocks-Markets-Economic Times
INDIAN Pride Hotels signs 141-key property in Indore Markets-Economic Times
COMPANIES Helmet maker Studds shares surges 18% as stricter traffic rules enforced in West Bengal Stocks-Markets-Economic Times
INDIAN US stocks: CrowdStrike shares fall as 'Mythos moment' fails to cheer investors Markets-Economic Times
COMPANIES NLC India OFS over-subscribed 5 times, institutional buyers put in Rs 4,158 cr bids Stocks-Markets-Economic Times

Nuvalent shares surge 39% to record high as GSK agrees to $10.6 billion acquisition deal

More from Market Samachar